Advances in inhibitors of MDM2 and MDM4

LI Chunhong; DU Hongjin; WEN Xiao′an; SUN Hongbin

doi:10.11665/j.issn.1000-5048.20150101

Journal of China Pharmaceutical University > 2015 > 46(1): 1-15. > DOI: 10.11665/j.issn.1000-5048.20150101

LI Chunhong, DU Hongjin, WEN Xiao′an, SUN Hongbin. Advances in inhibitors of MDM2 and MDM4[J]. Journal of China Pharmaceutical University, 2015, 46(1): 1-15. DOI: 10.11665/j.issn.1000-5048.20150101

Citation:

PDF (6078 KB)

Advances in inhibitors of MDM2 and MDM4

More Information

Graphical Abstract

Abstract

Abstract

The protein p53 plays an important role in the regulation of DNA repair, cell cycle arrest, apoptosis, senescence, autophagy and metabolism. MDM2 and MDM4 are the key negative regulatory proteins of p53. Inhibition of MDM2 and MDM4 has become a research hotspot in cancer therapy. Currently, seven MDM2 inhibitors(RG7112, MI-77301, RG7388, AMG232, CGM097, MK-8242, DS-3032b)and one MDM2/MDM4 dual inhibitor(ALRN-6924)have entered clinical trials. This paper highlights small molecule discovery, pharmacological activities and clinical research advances of MDM2 inhibitors in clinical trials, in addition, this review introduces research advances of MDM2/MDM4 dual inhibitors.
- MDM2,
- MDM4,
- inhibitor,
- p53,
- anti-tumor drug,
- advances

FullText(HTML)

References (84)

References

[1]	Lane DP,Crawford LV.T antigen is bound to a host protein in SV40-transformed cells[J].Nature,1979, 278(5701):261-263.
[2]	Vogelstein B,Lane D,Levine AJ.Surfing the p53 network[J].Nature,2000,408(6810):307-310.
[3]	Jin SK,Levine AJ.The p53 functional circuit[J].J Cell Sci,2001,114(23):4139-4140.
[4]	Feki A,Irminger-Finger I.Mutational spectrum of p53 mutations in primary breast and ovarian tumors[J].Crit Rev Oncol Hematol,2004,52(2):103-116.
[5]	Kruse JP,Gu W.Modes of p53 regulation[J].Cell,2009,137(4):623-634.
[6]	Jones SN, Roe AE, Donehower LA, et al. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53[J].Nature,1995,378(6553):206-208.
[7]	Parant J,Chavez-Reyes A,Little NA,et al.Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53[J].Nat Genet,2001,29(1):92-95.
[8]	Wade M,Li YC,Wahl GM,et al.MDM2,MDMX and p53 in oncogenesis and cancer therapy[J].Nat Rev Cancer,2013,13(2):83-96.
[9]	Chen LH,Agrawal S,Zhou WQ,et al.Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage[J].Proc Natl Acad Sci USA,1998,95(1):195-200.
[10]	Bottger A,Bottger V,Sparks A,et al.Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo[J].Curr Biol,1997,7(11):860-869.
[11]	Laurie NA,Donovan SL,Shih CS,et al.Inactivation of the p53 pathway in retinoblastoma[J].Nature,2006,444(7115):61-66.
[12]	Jean-Christophe WM,Michael AD,Aart GJ.MDMX:from bench to bedside[J].J Cell Sci,2007,120(3):371-378.
[13]	Vassilev LT,Vu BT,Graves B,et al.In vivo activation of the p53 pathway by small-molecule antagonists of MDM2[J].Science,2004,303(5659):844-848.
[14]	Levine AJ.p53,the cellular gatekeeper for growth and division[J].Cell,1997,88(3):323-331.
[15]	Momand J,Zambetti GP,Olson DC,et al.The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation[J].Cell,1992,69(7):1237-1245.
[16]	Cheok CF,Verma CS,Baselga J,et al.Translating p53 into the clinic[J].Nat Rev Clin Oncol,2011,8(1):25-37.
[17]	Wade M,Wang YV,Wahl GM.The p53 orchestra:MDM2 and MDMX set the tone[J].Trends Cell Biol,2010,20(5):299-309.
[18]	Freedman DA,Levine AJ.Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6[J].Mol Cell Biol,1998,18(12):7288-7293.
[19]	Wallace M,Worrall E,Pettersson S,et al.Dual-site regulation of MDM2 E3-ubiquitin ligase activity ligase activity[J].Mol Cell,2006,23(2):251-263.
[20]	Popowicz GM,Czarna A,Rothweiler U,et al.Molecular basis for the inhibition of p53 by Mdmx[J].Cell Cycle,2007,6(19):2386-2392.
[21]	Wang X.p53 regulation:teamwork between RING domains of MDM2 and MdmX[J].Cell Cycle,2011,10(24):4225-4229.
[22]	Wang X,Wang J,Jiang X.MdmX protein is essential for MDM2 protein-mediated p53 polyubiquitination[J].J Biol Chem,2011,286(27):23725-23734.
[23]	Mancini F,Di Conza G,Monti O,et al.Puzzling over MDM4-p53 network[J].Int J Biochem Cell Biol,2010,42(7):1080-1083.
[24]	Kussie PH,Gorina S,Marechal V,et al.Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain[J].Science,1996,274(5289):948-953.
[25]	Popowicz GM, Czarna A, Holak TA. Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain[J].Cell Cycle,2008,7(15):2441-2443.
[26]	Bottger V, Böttger A, Howard SF, et al. Identification of novel Mdm2 binding peptides by phage display[J].Oncogene,1996,13(10):2141-2147.
[27]	Bottger A,Böttger V,Garcia-Echeverria C,et al.Molecular characterization of the Hdm2-p53 interaction[J].J Mol Biol,1997,269(5):744-756.
[28]	Tovar C, Rosinski J, Filipovic Z, et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer:Implications for therapy[J].Proc Natl Acad Sci USA,2006,103(6):1888-1893.
[29]	Wang S,Zhao YJ,Bernard D,et al.Targeting the MDM2-p53 protein-protein interaction for new cancer therapeutics[J].Top Med Chem,2012, 8:57-80.
[30]	Khoo KH, Verma CS, Lane DP. Drugging the p53 pathway:understanding the route to clinical efficacy[J].Nat Rev Drug Discov,2014,13(3):217-236.
[31]	Zhao Y,Aguilar A,Bernard D,et al.Small-molecule inhibitors of the MDM2-p53 protein-protein interaction(MDM2 inhibitors)in clinical trials for cancer treatment[J].J Med Chem,2014,DOI: 10.1021/jm501092z.
[32]	Vu B,Wovkulich P,Pizzolato G,et al.Discovery of RG7112:a small-molecule MDM2 inhibitor in clinical[J].ACS Med Chem Lett,2013,4(5):466-469.
[33]	Tovar C, Graves B, Packman K, et al. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models[J].Cancer Res,2013,73(8):2587-2597.
[34]	US NIH. ClinicalTrials. gov. a)A study of RO5045337[RG7112] in patients with advanced solid tumors[EB/OL].(2007-11-15)[2015-01-20] .https://www.clinicaltrials.gov/ct2/show/NCT00559533.b)A study of RO5045337[RG7112] in patients with hematologic neoplasms[EB/OL].(2008-02-18)[2015-01-20] .https://www.clinicaltrials.gov/ct2/show/NCT00623870.c)A Study of RO5045337 in patients with liposarcomas prior to debulking surgery[EB/OL].(2010-06-11)[2015-01-20] .https://www.clinicaltrials.gov/ct2/show/NCT01143740.d)A Study of RO5045337 in patients with solid tumors[EB/OL].(2010-07-15)[2015-01-20] .https://www.clinicaltrials.gov/ct2/show/NCT01164033.e)An extension study of RO5045337 in patients participating in previous cancer Studies[EB/OL].(2012-08-30)[2015-01-20] .https://www.clinicaltrials.gov/ct2/show/NCT01677780.f)A study of RO5045337 in combination with doxorubicin in patients with soft tissue sarcoma[EB/OL].(2012-05-04)[2015-01-20] .https://www.clinicaltrials.gov/ct2/show/NCT01605526.g)A study of RO5045337 in combination with cytarabine in patients with acute myelogenous leukemia[EB/OL].(2012-06-12)[2015-01-20] .https://www.clinicaltrials.gov/ct2/show/NCT01635296.
[35]	Ray-Coquard I, Blay JY, Italiano A, et al. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified,well-differentiated or dedifferentiated liposarcoma:an exploratory proof-of-mechanism study[J].Lancet Oncol,2012,13(11):1133-1140.
[36]	Roche home.Promising data presented at ASH support continued development of multiple investigational medicines and demonstrate breadth of Roche′s robust hematology pipeline.[EB/OL].(2012-12-11)[2015-01-20] .http://www.roche.com/investors/updates/inv-update-2012-12-11.htm.
[37]	Yee K,Martinelli G,Assouline S,et al.Phase 1b study of the MDM2 antagonist RG7112 in combination with 2 doses/schedules of cytarabine[C]//Abstract of the 55nd ASH Annual Meeting and Exposition.New Orleans,2013.
[38]	Ding K,Lu YP,Zaneta NC,et al.Structure-based design of potent and non-peptide small-molecule inhibitors of the p53-MDM2 interaction[J].J Am Chem Soc,2005, 127(29):10130-10131.
[39]	Ding K,Lu YP,Zaneta NC,et al.Structure-based design of spiro-oxindoles as potent,specific small-molecule inhibitors of the MDM2-p53 interaction[J].J Med Chem,2006,49(12):3432-3435.
[40]	Shangary S,Qin D,McEachern D,et al.Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition[J].Proc Natl Acad Sci U S A,2008,105(10):3933-3938.
[41]	Yu S,Qin D,Shangary S,et al.Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction[J].J Med Chem,2009,52(24):7970-7973.
[42]	Zhao Y,Liu L,Sun W,et al.Diastereomeric spirooxindoles as highly potent and efficacious MDM2 inhibitors[J].J Am Chem Soc,2013,135(19):7223-7234.
[43]	Carry JC,Garcia-Echeverria C.Inhibitors of the p53/hdm2 protein-protein interaction-path to the clinic[J].Bioorg Med Chem Lett,2013,23(9):2480-2485.
[44]	Dos-Santos O,Lagarde P,P′erot G,et al.Human dedifferentiated liposarcomas growth inhibition by SAR299155,a potent and selective disruptor of the MDM2-p53 interaction[J].Eur J Cancer,2012,48(5):S25-S288.
[45]	Wang S,Sun W,Zhao Y,et al.SAR405838:an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression[J].Cancer Res,2014,74(20):5855-5865.
[46]	Zhao Y,Yu S,Sun W,et al.A potent small-molecule inhibitor of the MDM2-p53 interaction(MI-888)achieved complete and durable tumor regression in mice[J].J Med Chem,2013,56(13):5553-5561.
[47]	US NIH. ClinicalTrials. gov. a)Phase 1 safety testing of SAR405838[EB/OL].(2012-07-02)[2015-01-20] .https://www.clinicaltrials.gov/ct2/show/NCT01636479.b)A safety and efficacy study of SAR405838 and pimasertib in cancer patients[EB/OL].(2013-10-31)[2015-01-20] .https://www.clinicaltrials.gov/ct2/show/NCT01985191.
[48]	Ding Q,Zhang Z,Liu JJ,et al.Discovery of RG7388,a potent and selective p53-MDM2 inhibitor in clinical development[J].J Med Chem,2013,56(14):5979-5983.
[49]	Bartkovitz DJ. Substituted pyrrolidine-2-carboxamides: US, 20100152190[P].2010-06-17[2015-1-20] .
[50]	US NIH. ClinicalTrials. gov. a)A first-in-human study of RO5503781 in patients with advanced malignancies,except leukemia[EB/OL].(2011-10-27)[2015-1-20] .https://www.clinicaltrials.gov/ct2/show/NCT01462175.b)A study of RO5503781 as single agent or in combination with cytarabine in patients with acute myelogenous leukemia[EB/OL].(2013-01-18)[2015-01-20] .https://www.clinicaltrials.gov/ct2/show/NCT01773408.c)A study of the drug-drug interaction of RO5503781 and posaconazole,the relative bioavailability of new formulations of RO5503781 and the food-effect on the pharmacokinetics of RO5503781 in patients with solid tumors[EB/OL].(2013-07-09)[2015-01-20] .https://www.clinicaltrials.gov/ct2/show/NCT01901172.
[51]	Rew Y, Sun D. Discoveryof asmallmoleculeMDM2inhibitor(AMG232)for treating cancer[J].J Med Chem,2014,57(15):6332-6341.
[52]	Bernard D,Zhao Y,Wang S.AM-8553:a novel MDM2 inhibitor with a promising outlook for potential clinical development[J].J Med Chem,2012,55(11):4934-4935.
[53]	Sun D,Li Z,Rew Y,et al.Discovery of AMG 232,a potent,selective,and orally bioavailable MDM2-p53 inhibitor in clinical development[J].J Med Chem,2014, 57(4):1454-1472.
[54]	Rew Y,Sun D,Yan X,et al.Discovery of AM-7209,a potent and selective 4-amidobenzoic acid inhibitor of the MDM2-p53 interaction[J].J Med Chem,2014.doi: org/10.1021/jm501550p.
[55]	US NIH.ClinicalTrials.gov.a)A phase 1 study evaluating AMG 232 in advanced solid tumors[EB/OL].(2012-11-5)[2015-01-20] .https://www.clinicaltrials.gov/ct2/show/NCT01723020.b)A phase 1b study evaluating AMG 232 alone and in combination with trametinib in acute myeloid leukemia[EB/OL].(2013-11-21)[2015-01-20] .https://www.clinicaltrials.gov/ct2/show/NCT02016729.c)A phase 1b/2a atudy evaluating AMG 232 in metastatic melanoma[EB/OL].(2014-04-08)[2015-01-20] .https://www.clinicaltrials.gov/ct2/show/NCT02110355.
[56]	Joerg B.Substituted isoquinolinones and quinazolinones:WO,2011076786[P].2011-06-30[2015-01-20] .
[57]	Joerg B.Crystalline form of an inhibitor of MDM2/4 and p53 interaction:WO,2012066095[P].2012-05-24[2015-01-20]
[58]	US NIH.ClinicalTrials.gov.A phase I dose escalation study of CGM097 in adult patients with selected advanced solid tumors(CCGM097X2101)[EB/OL].(2013-01-02)[2015-01-20] .https://www.clinicaltrials.gov/ct2/show/NCT01760525.
[59]	US NIH.ClinicalTrials.gov.a)Study of MK-8242 alone and in combination with cytarabine in participants with acute myelogenous leukemia(P07649)[EB/OL].(2011-10-11)[2015-01-20] .https://www.clinicaltrials.gov/ct2/show/NCT01451437.b)Study of safety and pharmacokinetics of MK-8242 in participants with advanced solid tumors(P07650)[EB/OL].(2011-10-28)[2015-01-20] .https://www.clinicaltrials.gov/ct2/show/NCT01463696.
[60]	Ma Y.Substituted piperidines that increase p53 activity and the uses thereof:US,20080004287[P].2008-01-03[2015-01-20] .
[61]	Ma Y,Lahue BR,Gibeau CR,et al.Pivotal role of an aliphatic side chain in the development of an HDM2 inhibitor[J].ACSMed ChemLett,2014,5(5):572-575.
[62]	US NIH.ClinicalTrials.gov.A phase 1 multiple ascending dose study of DS-3032b,an oral murine double minute 2(MDM2)inhibitor,in subjects with advanced solid tumors or lymphomas[EB/OL].(2013-06-11)[2015-01-20] .https://www.clinicaltrials.gov/ct2/show/NCT01877382.
[63]	Miyazaki M, Naito H, Sugimoto Y, et al. Lead optimization of novel p53-MDM2 interaction inhibitors possessing dihydroimidazothiazole scaffold[J].Bioorg Med Chem Lett,2013,23(3):728-732.
[64]	Uoto K.Imidazothiazole derivative having 4,7-diazaspiro[2.5] octane ring structure:WO,2009151069[P].2009-12-12(2015-01-20).
[65]	Popowicz GM,Czarna A,Wolf S,et al.Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery[J].Cell Cycle,2010,9(5):1104-1111.
[66]	Patton JT,Mayo LD,Singhi AD,et al.Levels of HdmX expression dictate the sensitivity of normal and transformed cells to nutlin-3[J].Cancer Res,2006,66(6):3169-3176.
[67]	Graves B,Thompson T,Xia M,et al.Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization[J].Proc Natl Acad Sci U S A,2012,109(29):11788-11793.
[68]	Chang YS,Graves B,Guerlavais V,et al.Stapled α-helical peptide drug development:a potent dual inhibitor of MDM2 and MDMX for p53-dependentcancer therapy[J].Proc Natl Acad Sci U S A,2013,110(36):E3445-3454.
[69]	Böttger V,Böttger A,Garcia-Echeverria C,et al.Comparative study of the p53-MDM2 and p53-MDMX interfaces[J].Oncogene,1999,18(1):189-199.
[70]	Hu B,Gilkes DM,Chen J.Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX[J].Cancer Res,2007,67(18):8810-8817.
[71]	Phan J, Li Z, Kasprzak A, et al. Structure-based design of high affinity peptides inhibiting the interaction of p53 with MDM2 and MDMX[J].J Biol Chem,2010,285(3):2174-2183.
[72]	Pazgier M,Liu M,Zou G,et al.Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX[J].Proc Natl Acad Sci U S A,2009,106(12):4665-4670.
[73]	Li C,Pazgier M,Yuan W,et al.Systematic mutational analysis of peptide inhibition of the p53-MDM2/MDMX interactions[J].J Mol Biol,2010,398(2):200-213.
[74]	Kallen J,Goepfert A,Blechschmidt A,et al.Crystal structures of human MdmX(HdmX)in complex with p53 peptide analogues reveal surprising conformational changes[J].J Biol Chem,2009,284(13):8812-8821.
[75]	Bernal F,Wade M,Godes M,et al.A stapled p53 helix overcomes HDMX-mediated suppression of p53[J].Cancer Cell,2010,18(5):411-422.
[76]	US NIH. ClinicalTrials. gov. Safety study of ALRN-6924 in patients with advanced solid tumors[EB/OL].(2014-10-07)[2015-01-20] .https://www.clinicaltrials.gov/ct2/show/NCT02264613.
[77]	Lee JH,Kang E,Lee J,et al.Protein grafting of p53TAD onto a leucine zipper scaffold generates a potent HDM dual inhibitor[J].Nat Commun,2014.doi: 10.1038/ncomms4814.
[78]	Reed D,Shen Y,Shelat AA,et al.Identification and characterization of the first small molecule inhibitor of MDMX[J].J Biol Chem,2010,285(14):10786-10796.
[79]	Bista M,Smithson D,Pecak A,et al.On the mechanism of action of SJ-172550 in inhibiting the interaction of MDM4 and p53[J].PLoS One,2012,7(6):e37518.
[80]	Boettcher A.3-Imidazolyl-indoles for the treatment of proliferative disease:WO,2008119741[P].2008-10-09[2015-01-20] .
[81]	Lee JH,Zhang Q,Jo S,et al.Novel pyrrolopyrimidine-based α-helix mimetics:cell-permeable inhibitors of protein-protein interactions[J].J Am Chem Soc,2011,133(4):676-679.
[82]	Vogel SM, Bauer MR, Joerger AC, et al. Lithocholic acid is an endogenous inhibitor of MDM4 and MDM2[J].Proc Natl Acad Sci U S A,2012,109(42):16906-16910.
[83]	Boltjes A, Huang Y, van de Velde R, et al. Fragment-Based library generation for the discovery of a peptidomimetic p53-MDM4 inhibitor[J].ACS Comb Sci,2014,16(8):393-396.
[84]	Qin L,Yang F,Zhou C,et al.Efficient reactivation of p53 in cancer cells by a dual MdmX/MDM2 inhibitor[J].J Am Chem Soc,2014.doi: 10.1021/ja509223m.

[1]	YANG Qian, WANG Xiaojian. Research progress of sphingosine kinase 1 inhibitors[J]. Journal of China Pharmaceutical University, 2021, 52(6): 759-768. DOI: 10.11665/j.issn.1000-5048.20210615
[2]	LI Yin, GU Hongfeng, ZOU Yi, WANG Shuping, XU Yungen. Research progress of mono-(ADP-ribosyl) transferase family and their inhibitors in tumor therapy[J]. Journal of China Pharmaceutical University, 2021, 52(6): 643-652. DOI: 10.11665/j.issn.1000-5048.20210601
[3]	BU Hong, ZHOU Jinpei, ZHANG Huibin. Research progress of mitogen-activated protein kinase interacting kinases inhibitors in tumor immunotherapy[J]. Journal of China Pharmaceutical University, 2021, 52(4): 410-421. DOI: 10.11665/j.issn.1000-5048.20210403
[4]	FENG Yang, XU Xiao, MO Ran. Advances in lymphatic targeted drug delivery system for treatment of tumor metastasis[J]. Journal of China Pharmaceutical University, 2020, 51(4): 425-432. DOI: 10.11665/j.issn.1000-5048.20200406
[5]	TIAN Jiping, ZHANG Jian, ZHOU Jinpei, ZHANG Huibin. Advances in small molecule inhibitors of PD-1/PD-L1 immune checkpoint pathway[J]. Journal of China Pharmaceutical University, 2019, 50(1): 1-10. DOI: 10.11665/j.issn.1000-5048.20190101
[6]	LIU Kejun, ZHANG Zhimin, RAN Ting, CHEN Hongli, LU Tao, CHEN Yadong. Advances in BET bromodomain protein inhibitors[J]. Journal of China Pharmaceutical University, 2015, 46(3): 264-271. DOI: 10.11665/j.issn.1000-5048.20150302
[7]	ZHANG Yuan, CHENG Yulan, ZHOU Jinpei, ZHANG Huibin. Advances on receptor tyrosine kinase inhibitors taking c-Met as anti-tumor target[J]. Journal of China Pharmaceutical University, 2015, 46(1): 16-27. DOI: 10.11665/j.issn.1000-5048.20150102
[8]	LI Chunhong, DU Hongjin, WEN Xiao′an, SUN Hongbin. Advances in inhibitors of MDM2 and MDM4[J]. Journal of China Pharmaceutical University, 2015, 46(1): 1-15. DOI: 10.11665/j.issn.1000-5048.20150101
[9]	DENG Lian-bai, LI Ai-xiu, JIN Yu-rui. Advances in the study on inhibitors of RNase H,a novel anti-HIV drug target[J]. Journal of China Pharmaceutical University, 2011, 42(6): 578-584.
[10]	KONG Kai-lai, LU Shuai, GAO Yi-ping, YANG Pei, TANG Wei-fang, LU Tao. Advances on the study of PLK1 inhibitors as antitumor agents[J]. Journal of China Pharmaceutical University, 2011, 42(1): 9-15.

Cited By

Cited by

Periodical cited type(2)

1.	郁莉，蒋颖敏，许磊，朱景宇. 分子对接与分子动力学模拟法探究PI3Kδ/度维利塞(Duvelisib)的选择性结合. 化学研究与应用. 2022(02): 341-348 .
2.	蔡燕飞，陈蕴，史劲松，金坚. 抗肿瘤药物体外药效学评价结合细胞生物学实验教学促进教研融合. 实验室研究与探索. 2020(08): 192-195 .

Other cited types(0)

Get Citation

PDF

XML

Article views (2514) PDF downloads (3994) Cited by(2)

Turn off MathJax

Article Contents

Abstract

References

Advances in inhibitors of MDM2 and MDM4

Abstract

References

Related Articles

Cited by

Periodical cited type(2)

Other cited types(0)

Catalog

Advances in inhibitors of MDM2 and MDM4

Abstract

References

Related Articles

Cited by

Periodical cited type(2)

Other cited types(0)

Catalog

Export File

Citation

Format

Content